DCN: 20-003431 v.1.0



100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	25-Jun-2020	25-Jun-2023	: Date of Next Review
Prepared By:	Amy Hosein	Not Applicable	: Supersedes
QA/QC Approval:	Carissa McCollian	Wendy Santay	: Management Approval
Reason for Revision:	See Revision History in ensur.		

CERTIFICATE OF **A**NALYSIS

POTASSIUM BROMIDE BIO ACTIVE GRADE / PB2220-G500

LOT#: PB2220-009-0620

KBr * F.W. 119.00 g/mol * CAS#; 7758-02-3 Manufacturing Date: 6/12/20 Retest Date: 6/30/22 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013

Packaging Date: 6/14/20 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Meets or exceeds USP Specifications

TEST		SPECIFICATION	TEST RESULT		
Acidity or Alkalinity		Passes Test	Passes Test		
Appearance of Solution		Clear and Colorless	Clear and Colorless		
Assay		98.0 - 100.5%	100.4%		
Bromates		Passes Test	Passes Test		
Heavy Metals		10 ppm max.	< 10 ppm		
T.1	A	Passes Test	Passes Test		
Identification	В	Passes Test	Passes Test		
Iodides		Passes Test	Passes Test		
Limit of Chlorine		0.6% max.	<0.6%		
Limit of Iron		20 ppm max.	< 20 ppm		
Loss on Drying		1.0% max.	0.1%		
Magnesium and Alkaline Earth-Metals		0.02% max.	<0.02%		
Sulfates		0.01% max.	<0.01%		
	Arsenic (As)	5 ppm max.	< 5 ppm		
Turk Metala	Copper (Cu)	5 ppm max.	< 5 ppm		
Trace Metals	Iron (Fe)	5 ppm max.	< 5 ppm		
	Lead (Pb)	5 ppm max.	< 5 ppm		

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: 16-001310

DCN: 20-003431 v.1.0

<u>CAUTION STATEMENT:</u> For use in development only not for commercial distribution.

CAUTION STATEMENT: Rx only.

INTENDED USE: Material represented by this Certificate of Analysis is suitable for use as a non-Sterile Active Pharmaceutical Ingredient manufactured in accordance with the ICH Q7 Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as a Sterile or Injectable Active Pharmaceutical Ingredient, Drug Product or Household Item.

STATEMENT: Meets the chemical testing specifications of the current edition of the European Pharmacopoeia.

OVI STATEMENT: Based on the manufacturing process and the controlled handling, storage and analysis of this product, this product complies with the requirements and specifications listed in the current USP method <467> Tables 1, 2, 3, or 4.

Prepared by:	_Date: _	10129120	Job Title:	QA Supervisor
Reviewed by:	Date:	6/29/20	Job Title:	QC Manager